Top Page
IVD Medical Holding Limited
(1931)
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
IVD Medical Holding Limited Business Overview & Revenue Model
IVD Medical Holding Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.08B | 3.16B | 3.09B | 2.75B | 2.73B | 2.43B |
| Gross Profit | 706.08M | 751.17M | 671.70M | 608.14M | 566.27M | 476.17M |
| EBITDA | 401.57M | 475.96M | 397.93M | 349.66M | 286.17M | 250.04M |
| Net Income | 174.25M | 260.42M | 238.16M | 210.00M | 174.54M | 158.72M |
Balance Sheet | ||||||
| Total Assets | 6.16B | 5.52B | 4.79B | 4.31B | 4.37B | 3.91B |
| Cash, Cash Equivalents and Short-Term Investments | 427.55M | 1.86B | 1.24B | 1.04B | 841.78M | 794.74M |
| Total Debt | 1.67B | 755.97M | 344.32M | 349.92M | 427.65M | 421.80M |
| Total Liabilities | 2.63B | 1.76B | 1.40B | 1.16B | 1.37B | 1.05B |
| Stockholders Equity | 3.47B | 3.71B | 3.34B | 3.15B | 2.98B | 2.85B |
Cash Flow | ||||||
| Free Cash Flow | 99.21M | 88.69M | 251.92M | 215.39M | 137.88M | 144.87M |
| Operating Cash Flow | 136.55M | 140.29M | 292.42M | 249.67M | 163.11M | 170.49M |
| Investing Cash Flow | -2.00M | -57.80M | -77.58M | 60.54M | -27.88M | -196.00M |
| Financing Cash Flow | -18.46M | 395.13M | -19.45M | -191.29M | -66.29M | -63.24M |
IVD Medical Holding Limited Technical Analysis
IVD Medical Holding Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$60.95B | 8.29 | 8.74% | 3.75% | -2.68% | -21.45% | |
71 Outperform | $66.20B | 7.14 | 7.53% | 2.67% | 2.77% | 39.24% | |
65 Neutral | HK$7.32B | 20.83 | 6.77% | 2.72% | 29.81% | 10.40% | |
64 Neutral | HK$3.60B | 19.14 | 5.07% | 3.81% | 0.33% | -44.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$656.30M | -0.59 | -69.05% | ― | -43.86% | -217.25% |
IVD Medical Holding Limited Corporate Events
IVD Medical Holding Limited announced that during its extraordinary general meeting held on November 26, 2025, a special resolution to change the company’s English name was passed with unanimous support. This decision reflects a strategic move that could impact the company’s brand identity and market positioning, potentially influencing stakeholder perceptions and future business operations.
IVD Medical Holding Limited has announced its acquisition of a significant stake in B-Soft Co., Ltd, a move that positions the company to hold approximately 12.64% of the voting rights in B-Soft. This strategic acquisition, valued at RMB500 million, involves the purchase of 96,525,096 A shares, representing 6.23% of B-Soft’s total issued share capital. Additionally, the company has secured voting rights for an additional 195,780,282 A shares through agreements with the vendor and a private fund. This transaction is classified as a discloseable transaction under Chapter 14 of the Listing Rules, requiring reporting and announcement but exempt from shareholder approval. The acquisition is contingent on regulatory approvals and other conditions, and stakeholders are advised to exercise caution.
IVD Medical Holding Limited has announced that it is in discussions to potentially acquire control over B-Soft Co., Ltd., a company listed on the ChiNext Board of the Shenzhen Stock Exchange. The transaction, if completed, could significantly impact IVD Medical’s market positioning by expanding its influence in the Chinese market. However, the transaction is still under negotiation, and there are various conditions and approvals required before it can proceed. Shareholders are advised to exercise caution as the deal may not materialize.
IVD Medical Holding Limited has announced an extraordinary general meeting scheduled for November 26, 2025, to consider a special resolution for changing its English name to ETHK Labs Inc. This change, pending approval from the Cayman Islands Registrar of Companies, signifies a strategic rebranding effort that could impact the company’s market positioning and stakeholder perception.
IVD Medical Holding Limited announced significant strategic advancements, including the development of the ivd.xyz Exchange, the world’s first real-world asset exchange ecosystem for medical innovative drugs. This initiative aims to address industry challenges such as low financing efficiency and poor asset liquidity. The company is also progressing with its IVDD stablecoin program, designed to facilitate efficient cross-border transactions within its ecosystem. These moves are expected to enhance the company’s capital efficiency, accelerate drug development, and bridge the gap between medical innovation and crypto-financial markets.
IVD Medical Holding Limited has announced a proposed change of its English name to ‘ETHK Labs Inc.’ to better reflect its new strategic positioning and future development direction. This change is part of the company’s evolution into a global high-tech intellectual property capital operation platform, emphasizing a strategy of ‘financing-M&A-integration-exit’ to create sustainable returns for shareholders. The change will not affect shareholders’ rights or the company’s daily operations, and the company will also update its logo to align with the new name.
IVD Medical Holding Limited announced a change in its audit committee, with Ms. Tai Yang stepping down as a member effective October 20, 2025. This change is part of a broader redesignation of directors and board committee compositions, which may impact the company’s governance and operational oversight.
IVD Medical Holding Limited has announced the composition of its board of directors and their respective roles and functions. This announcement outlines the structure of the board and its committees, which is crucial for stakeholders to understand the governance and strategic direction of the company.
IVD Medical Holding Limited, a company incorporated in the Cayman Islands, has announced a significant change in its board structure. Ms. Tai Yang has been redesignated from an independent non-executive director to an executive director, effective October 20, 2025. This change also involves her stepping down from the Remuneration Committee, with Mr. Zhang Jianlei taking her place. The redesignation is part of the company’s strategic adjustments and reflects Ms. Tai’s extensive background in management and finance, which is expected to contribute positively to the company’s operations and governance.
IVD Medical Holding Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement outlines the structure of the board’s committees, which include the Audit, Remuneration, and Nomination Committees, reflecting the company’s governance framework and potentially impacting its strategic direction and stakeholder engagement.
IVD Medical Holding Limited has acquired a property in Irvine, California, and established a US subsidiary, ETHK BANK, to advance its initiatives in stablecoins and intellectual property securitization. This strategic move aims to enhance the company’s global business synergy and create long-term value for shareholders by developing a stablecoin public blockchain technology and innovative capital operations in North America.
IVD Medical Holding Limited has confidentially submitted a draft registration statement with the U.S. SEC for a proposed dual listing on NASDAQ, marking a strategic move in its global expansion. This dual listing is expected to enhance the company’s financing opportunities, brand influence, share liquidity, corporate governance, and strategic flexibility, thereby strengthening its position in international markets.
IVD Medical Holding Limited has entered into a strategic cooperation agreement with Transcenta Holding Limited to explore the RWA Tokenization of assets related to six innovative drug pipelines, valued at over US$1.5 billion. This collaboration signifies a significant milestone in integrating technology and finance, as it marks the formal entry of high-value innovative drug intellectual property assets into capital markets in the form of RWA. The initiative will focus on advancing these drug pipelines using cutting-edge technology platforms, potentially offering First-in-Class or Best-in-Class treatments in the oncology field.
IVD Medical Holding Limited has announced a corporate rebranding, unveiling a new logo to reflect its strategic shift towards a global on-chain financial ecosystem. This change signifies the company’s commitment to becoming a leader in digital industry innovation, leveraging blockchain technology to build a robust and interconnected financial infrastructure. The new logo embodies the company’s vision of open empowerment and ecological interconnectivity, marking its evolution into the ‘ETHK Ecosystem’ era.
IVD Medical Holding Limited has inaugurated the ETHK Tower in Nanjing, China, marking a significant advancement in their ‘ETHK On-Chain Financial Ecosystem Strategy.’ This development positions the company as a leader in the RWA technology domain, offering a state-of-the-art facility for R&D and ecosystem empowerment. The ETHK Tower will serve as a hub for global RWA technology research, featuring world-class laboratories, data centers, and collaborative workspaces. It aims to host over 5,000 specialists, forming a robust R&D team to drive innovation and provide comprehensive digital solutions for enterprise and institutional clients.
IVD Medical Holding Limited has announced a strategic cooperation with Renhe International to establish the world’s first nonprescription medicines vertical RWA exchange in the United States. This collaboration is part of IVD’s broader strategy to develop a global on-chain financial ecosystem under its ETHK brand, which includes the creation of a decentralized financial platform and a focus on digital asset transformation. The company is also proposing a name change to reflect its new positioning as a technology driver within this ecosystem. The new ‘Exchange within Exchange’ model aims to enhance global asset circulation and efficiency by creating a B2B trading ecosystem for real-world assets, thus reshaping the asset value distribution model across industries.
IVD Medical Holding Limited has announced the establishment of joint ventures with ETHK Group, focusing on the development of a global on-chain financial ecosystem. The joint ventures, ETHK Inc and ETHK HOLDINGS LIMITED, aim to create a secure, efficient, and decentralized financial platform while strategically integrating industry players and resources to enhance the ecosystem’s competitive edge and potential for future growth.
IVD Medical Holding Limited has proposed changing its name to ETHK Labs Inc. to better reflect its strategic shift towards digital industries and on-chain financial ecosystems. This change is part of the company’s broader strategy to position itself as a global leader in digital technology and innovation, providing comprehensive technology solutions for the ETHK on-chain financial ecosystem and its global partners.